SAM
RCKT icon

Smartleaf Asset Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Smartleaf Asset Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20
Closed -$151 – 2924
2025
Q1 		$151 Sell
20
-229
-92% -$2.26K ﹤0.01% 2823
2024
Q4 		$3K Sell
249
-158
-39% -$2.38K ﹤0.01% 2416
2024
Q3 		$7.51K Buy
407
+24
+6% +$492 ﹤0.01% 1925
2024
Q2 		$8.21K Buy
+383
New +$8.8K ﹤0.01% 1514

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Smartleaf Asset Management's RCKT Position: Q2 2025 in Review

Smartleaf Asset Management sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 20 shares — an estimated $151 sold.

Smartleaf Asset Management first reported a position in RCKT in Q2 2024 and held it in 4 quarters. The position peaked at $8.21K in Q2 2024. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

  • Smartleaf Asset Management reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Smartleaf Asset Management sold 20 Rocket Pharmaceuticals shares in Q2 2025, an estimated $151.
  • Smartleaf Asset Management first reported a position in Rocket Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Smartleaf Asset Management's Rocket Pharmaceuticals position peaked at $8.21K in Q2 2024.
  • 196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on Smartleaf Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.